AMRX vs DASH · P/E 44, rev $2.79B vs P/E 76, rev $13.72B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus DoorDash, Inc. Class A Common Stock (DASH) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Not investment advice. Open the AMRX and DASH stock pages for the full models.
Not investment advice.